The US Food and Drug Administration (FDA) has approved a new drug that can be used as a weight loss drug.
Wegovy is specifically for chronic weight management in overweight or obese adults with ‘at least one weight-related comorbidity’, according to the pharmaceutical company Novo Nordisk, the manufacturer of the medicine. Wegovy is a higher dose of semaglutide for Novo’s diabetes.
In company-funded studies, participants taking Wegovy had an average weight loss of 1
In particular, the anti-obesity drug Novo causes weight loss in patients by reducing hunger while increasing the feeling of satiety.
CLICK HERE TO READ MORE ABOUT FOX BUSINESS
The drug, which is injected by the patient once a week, is intended to be used in addition to diet and exercise, according to Novo.
Wegovy’s four-week offer, which is essentially four injections, will cost consumers about $ 1,300.
The product is available on prescription by a medical professional and is expected to be available in pharmacies later this month.
GET THE FOX BUSINESS, CLICK HERE
“Despite the best efforts to lose weight, many obese people struggle to achieve and maintain weight loss due to physiological responses that promote weight recovery,” said Martin Holst Lange, executive vice president of development at Novo Nordisk.
According to Lange, this marks a “new era in the treatment of obesity.”
The Associated Press contributed to this report